Ischemaview, Inc.: FDA filings under this applicant name
FDA lists 26 510(k) clearances under 4 spellings of the applicant name “Ischemaview, Inc.” (first 2013, latest 2026), across 5 product codes in 1 review panel. Median 510(k) review time under this name: 106 days. Since 2017 the median was 103 days, against 130 days for all cleared 510(k)s in the same product codes. Related companies, subsidiaries and acquired businesses that file under other applicant names are counted on their own pages, not here.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2013 | 1 | 507 |
| 2014 | 0 | — |
| 2015 | 0 | — |
| 2016 | 0 | — |
| 2017 | 0 | — |
| 2018 | 2 | 194 |
| 2019 | 0 | — |
| 2020 | 3 | 94 |
| 2021 | 0 | — |
| 2022 | 4 | 100 |
| 2023 | 4 | 123 |
| 2024 | 3 | 172 |
| 2025 | 6 | 90 |
| 2026 | 3 | 103 |
Review time against the same product codes
Since 2017, 510(k)s cleared under the name Ischemaview, Inc. took a median 103 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 130 days.
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| QAS | Radiological Computer-Assisted Triage And Notification Software | 11 | 11 |
| LLZ | System, Image Processing, Radiological | 6 | 6 |
| QIH | Automated Radiological Image Processing Software | 6 | 6 |
| POK | Computer-Assisted Diagnostic Software For Lesions Suspicious For Cancer | 2 | 2 |
| QFM | Radiological Computer-Assisted Prioritization Software For Lesions | 1 | 1 |
Review panels
- Radiology (26)
Most recent Ischemaview, Inc. 510(k) clearances
| 510(k) | Device | Product code | Decision date | Review days |
|---|---|---|---|---|
| K262301 | Rapid ICH (v4.0) | QAS | 2026-10-09 | 94 |
| K261368 | Rapid Platform (R6.7) | QIH | 2026-09-21 | 147 |
| K261085 | Rapid Vessel Occlusion (Rapid VO) | QAS | 2026-07-13 | 103 |
| K251987 | Rapid Aortic Measurements | QIH | 2025-09-23 | 88 |
| K251533 | Rapid Obstructive Hydrocephalus, Rapid OH | QAS | 2025-09-04 | 108 |
| K252526 | Rapid DeltaFuse | LLZ | 2025-08-26 | 15 |
| K251151 | Rapid CTA 360 | QAS | 2025-07-16 | 93 |
| K243378 | Rapid MLS | QIH | 2025-05-28 | 210 |
| K243350 | Rapid Neuro3D | QIH | 2025-01-22 | 86 |
| K233582 | Rapid | LLZ | 2024-04-22 | 172 |
16 earlier clearances. See the full list in Caduvo.
Recalls
FDA recall records list no recalls under a recalling firm named Ischemaview, Inc..
Recalling firms are matched to this applicant name by name only (same normalization), so related entities that recall under another name are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
FDA spellings included
FDA records this applicant under 4 spellings (case, punctuation and legal-suffix variants of one name); this page adds them up. Filings per spelling:
- Ischemaview, Inc. (23)
- Ischemaview (1)
- Ischemaview Incorporated (1)
- iSchemaview (1)
Frequently asked questions
How many FDA 510(k) clearances are listed under Ischemaview, Inc.?
FDA lists 26 510(k) clearances under 4 spellings of the applicant name “Ischemaview, Inc.” (first 2013, latest 2026), across 5 product codes in 1 review panel. Filings under other applicant names, such as subsidiaries, are not included.
How long has FDA taken to clear 510(k)s filed by Ischemaview, Inc.?
The median time from FDA receipt to decision across 510(k)s cleared under the name Ischemaview, Inc. is 106 days. Since 2017: 103 days, versus 130 days for all cleared 510(k)s in the same product codes.
Which FDA product codes appear under Ischemaview, Inc.?
The most frequent FDA product codes under this applicant name are QAS (Radiological Computer-Assisted Triage And Notification Software, 11); LLZ (System, Image Processing, Radiological, 6); QIH (Automated Radiological Image Processing Software, 6).
Next steps
- See all 26 Ischemaview, Inc. clearances with predicates and recalls
- Run predicate analysis for product code QAS, Ischemaview, Inc.'s most frequent
Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this data. Data and corrections policy.